Discover
ELVN
Enliven Therapeutics, Inc.
40.98
2 x 28.80
2 x 50.62
bid
ask
+
0.35
0.86%
2 @ 04:00 PM
40.98 +0.00 (0.00%)
| Ytd | 166.10% | |
| 1y | 92.48% |
40.29
day range
41.97
15.14
52 week range
61.15
| Open | 41.00 | Prev Close | 40.63 | Low | 40.29 | High | 41.97 | Mkt Cap | 3.00B |
| Vol | 1.00M | Avg Vol | 1.13M | EPS | -1.67 | P/E | N/A | Forward P/E | -17.41 |
| Beta | 0.34 | Short Ratio | 9.80 | Inst. Own | 114.14% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 11-11 | 50-d Avg | 54.25 | 200-d Avg | 40.93 | 1yr Est | 73.67 |
Earning
| Date | For | Estimate | Reported | Surprise | surprise % |
|---|---|---|---|---|---|
| 2026-11-11 | 2026-09 | -0.46 | N/A | N/A | N/A |
| 2026-08-05 | 2026-06 | -0.39 | -0.49 | -0.1 | -26.56% |
| 2026-05-07 | 2026-03 | -0.44 | -0.38 | 0.06 | 13.64% |
| 2026-03-03 | 2025-12 | -0.42 | -0.48 | -0.06 | -14.29% |
| 2025-11-12 | 2025-09 | -0.43 | -0.32 | 0.11 | 25.58% |
| 2025-08-13 | 2025-06 | -0.53 | -0.49 | 0.04 | 7.55% |
Upgrade / Downgrade
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| 2026-10-02 | Morgan Stanley | Upgrade | Overweight | |
| 2026-10-01 | JP Morgan | Upgrade | Overweight | |
| 2026-08-18 | William Blair | Upgrade | Outperform | |
| 2026-08-18 | Barclays | Upgrade | Overweight | |
| 2026-08-18 | Mizuho | Upgrade | Outperform | Outperform |
| 2026-08-06 | Stifel | Upgrade | Buy | Buy |
Profile
Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. Its clinical programs comprise ELVN-001, a small molecule kinase inhibitor which is in Phase 1 clinical trial to treat adults with chronic myeloid leukemia; and ELVN-002, a central nervous system (CNS) penetrant and irreversible human epidermal growth factor receptor 2 inhibitor that is in Phase 1 clinical trial for the treatment of non-small cell lung cancer (NSCLC) and other HER2 mutant tumors. The company was founded in 2019 and is headquartered in Boulder, Colorado.
Insider Holder
| Date | Name | Relation | Quantity | Description |
|---|---|---|---|---|
| 2026-09-16 | COLLINS HELEN LOUISE | Officer | 25.00K | Conversion of Exercise of derivative security |
| 2026-08-03 | DERYNCK MIKA K | Director | 0.00 | Conversion of Exercise of derivative security |
| 2026-09-30 | GARLAND J SCOTT | Director | 0.00 | Conversion of Exercise of derivative security |
| 2026-02-16 | HEYMAN RICHARD A | Director | 0.00 | Sale |
| 2026-09-16 | HOHL BENJAMIN | Chief Financial Officer | 38.00K | Conversion of Exercise of derivative security |
| 2025-11-16 | KINTZ SAMUEL | Chief Executive Officer | 0.00 | Sale |
Institution Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2026-06-29 | FMR, LLC | 10.03M | 410.83M | 13.68% |
| 2026-06-29 | Orbimed Advisors LLC. | 6.78M | 277.71M | 9.25% |
| 2026-06-29 | Polar Capital Holdings PLC | 6.43M | 263.53M | 8.78% |
| 2026-06-29 | Blackrock Inc. | 4.36M | 178.66M | 5.95% |
| 2026-06-29 | Vestal Point Capital, LP | 4.00M | 163.92M | 5.46% |
| 2026-06-29 | Commodore Capital Lp | 3.28M | 134.21M | 4.47% |
Fund Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2026-06-29 | VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 1.88M | 77.18M | 2.57% |
| 2026-08-30 | Fidelity Select Portfolios-Select Health Care Portfolio | 1.28M | 52.45M | 1.75% |
| 2026-07-30 | Fidelity Securities Fund-Fidelity Small Cap Growth Fund | 1.25M | 51.26M | 1.71% |
| 2026-08-30 | iShares Trust-iShares Russell 2000 ETF | 1.10M | 45.10M | 1.50% |
| 2026-06-29 | T. Rowe Price New Horizons Fund, Inc. | 807.33K | 33.08M | 1.10% |
| 2026-08-30 | Fidelity Rutland Square TRT II-Strategic Advisers Fidelity U.S. Total | 737.60K | 30.23M | 1.01% |